Spots Global Cancer Trial Database for Educate and Improve Underserved Populations' Uptake and Completion of the HPV Vaccine

Study Description

Brief Summary: The educational intervention to be delivered by the CHE(Community Health Educator) consists of "toolkit education materials" developed by the National Cancer Institute (NCI) and a small media intervention (i.e., video) that our research team has developed. The NCI-produced toolkit education materials consist of Power Point presentations, flyers, and posters that contain information about HPV(Human Papilloma Virus), HPV-related cancers, and the importance of the HPV vaccine series for adolescents (9-17 years old) and young adults (18-26 year old) who are eligible for the vaccine.

Detailed Description: The investigator will use a one-group pre- and post-test design to assess the effects of the intervention on the primary outcomes. The educational intervention will be delivered to 200 participants by a trained CHE who will conduct educational workshops to deliver the educational materials at DHHA outpatient clinics. The CHE will administer the pre- and post-intervention survey to workshop participants. The follow-up survey will occur over the phone at 3 months post baseline only for parent participants that indicate having unvaccinated children or are a young adult participant and indicated not being vaccinated at baseline. The last follow up survey will occur over the phone at 6 months only for those parent participants that indicated having unvaccinated children at the 3 month follow up call, or are a young adult participant and indicated not being vaccinated at the 3 month follow up call. Additionally, the investigator will use a one-group post-test design to assess the impact of the intervention on the secondary outcomes. At the patient-level, the investigator will track participants that receive (a) 1st dose, 2nd dose, or 3rd dose of the HPV vaccine; and the number of referrals to care by recording the number of patients received (b) referrals to health insurance, discount or no-cost HPV vaccine programs; or (c) to other services to facilitate HPV vaccine dose completion. To assess clinic-level impact, the investigator will track each clinic's HPV vaccine rates for adolescents (9-17 years old) and young adults (18-26), and compare rates from before the investigator started the intervention and then quarterly there after the investigator had introduced the intervention to each respective Denver Health clinic.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: Yes

Locations

Contact Details

Useful links and downloads for this trial